AB103. Prostatectomy versus active surveillance for early stage prostate cancer: a meta-analysis

OBJECTIVE: To compare the survival effect between radical prostatectomy (RP) and active surveillance (AS) for the treatment of early stage prostate cancer. METHOD: Randomized controlled trials were computerized searched from Medline, Cochrane Library, ISI web of knowledge, Science Direct, Google scholar, CBM database for the evaluation of prognosis of treatment for early stage prostate cancer—RP versus AS. Prognosis of the treatment includes all-cause mortality, prostate cancer specific mortality and cancer metastasis. The latest retrieval date was May 2014. The data was extracted and the quality of included studies was independently assessed by two reviewers and RevMan5.2 software was used to perform data synthesis. RESULT: Three RCTs involving 1,537 patients (772 RP vs. 765 AS) were included finally. The results of meta-analysis displayed that the hazard of all-cause mortality in RP group was significantly lower than AS group, HR =0.79 (95% CI, 0.69-0.90, P=0.0005), no significant difference was seen in <65 years group or ≥65 years group. Prostate cancer specific mortality risk was HR =0.58 (95% CI, 0.44-0.76), P=0.0001). And subgroup analysis showed RP protect patients from cancer specific mortality by age under 65 years, HR=0.46 (95% CI, 0.31-0.68, P=0.0001), no significant difference in patients above 65 years. Hazard of tumor metastasis was lower in RP group than in AS group regardless of age stratification, HR =0.54 (95% CI, 0.42-0.68, P<0.00001). CONCLUSIONS: Radical prostatectomy reduced hazard of all-cause mortality, cancer specific mortality and cancer metastasis, and the benefit to prostate cancer survival was mainly manifested in patients under age 65 years. After combining patient expectant survival assessment and quality of life, active surveillance was still an effective management protocol for early stage prostate cancer.